A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers.
Kyi C, Sabado R, Blazquez A, Posner M, Genden E, Miles B, Khorasani H, Dottino P, Irie H, Port E, Wolf A, Cho H, Parekh S, Mandeli J, Galsky M, Oh W, Gnjatic S, Schadt E, Friedlander P, Bhardwaj N. A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers. Journal Of Clinical Oncology 2017, 35: tps3114-tps3114. DOI: 10.1200/jco.2017.35.15_suppl.tps3114.Peer-Reviewed Original ResearchPhase I studyClinical trialsAdjuvant treatmentSolid cancersCommon Terminology Criteria for Adverse Events v5.0Epitope-specific T cell responsesDevelopment of immunotherapeutic approachesTreatment of solid tumorsAdjuvant treatment of solid tumorsTreatment of solid cancersLobular breast cancerT cell responsesBlood samplesImmune response monitoringSingle-center studyPeripheral blood samplesDisease recurrence riskCellular immune responsesAdministered 1 dayUterine adnexaSerous carcinomaImmunotherapeutic approachesPoly-ICLCTumor antigensHistological diagnosis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply